CD33 and SHP-1/PTPN6 Interaction in Alzheimer's Disease

Area of Science:

• Neuroimmunology
• Genetics
• Molecular Biology

Background:

• Large-scale genetic studies reveal innate immune cells' role in Alzheimer's disease (AD) susceptibility.
• CD33, a myeloid cell protein, is a key genetic risk factor for AD.
• AD-associated genetic variants in CD33 alter its expression and function, particularly the large isoform (CD33M).

Purpose of the Study:

• To investigate how AD-associated genetic variations in CD33 impact its interaction with SHP-1 in human microglia.
• To explore the functional consequences of these genotype-dependent interactions in the context of AD risk.

Main Methods:

• Utilized molecular and computational approaches.
• Examined interactions in human microglia and microglia-like cells.
• Analyzed gene-gene interactions involving CD33, PTPN6 (SHP-1), and PTPN11 (SHP-2).

Main Results:

• Demonstrated a genotype-dependent interaction between CD33 and SHP-1 in microglia.
• This interaction is suggested to functionally contribute to AD risk associated with the CD33 variant.
• Found that CD33-PTPN6 (SHP-1) gene-gene interactions affect AD-related traits, but CD33-PTPN11 (SHP-2) interactions do not.

Conclusions:

• Genetic variation in CD33 influences its interaction with SHP-1, a mechanism potentially underlying AD susceptibility.
• The interplay between CD33 and SHP-1 represents a significant pathway in AD pathogenesis.
• Specific gene-gene interactions, like CD33-SHP-1, are relevant to AD, while others, like CD33-SHP-2, are not.